Simulations Plus (NASDAQ:SLP) Sets New 1-Year Low - Time to Sell?

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $26.51 and last traded at $26.51, with a volume of 24606 shares traded. The stock had previously closed at $30.39.

Analyst Ratings Changes

A number of brokerages have weighed in on SLP. StockNews.com cut Simulations Plus from a "hold" rating to a "sell" rating in a research note on Monday, November 4th. KeyCorp decreased their price target on shares of Simulations Plus from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Wednesday. Stephens initiated coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an "overweight" rating and a $39.00 price objective on the stock. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a report on Wednesday. Finally, BTIG Research lowered their price target on Simulations Plus from $60.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Simulations Plus presently has an average rating of "Moderate Buy" and an average target price of $49.00.

Simulations Plus Price Performance

The firm has a market capitalization of $566.60 million, a price-to-earnings ratio of 57.57 and a beta of 0.80. The business's 50 day moving average price is $29.80 and its 200-day moving average price is $34.04.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $18.70 million for the quarter, compared to analysts' expectations of $19.73 million. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm's quarterly revenue was up 19.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.18 EPS. As a group, analysts expect that Simulations Plus, Inc. will post 1.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the sale, the director now owns 3,442,584 shares of the company's stock, valued at $109,336,467.84. The trade was a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds have recently bought and sold shares of the company. First Horizon Advisors Inc. lifted its holdings in shares of Simulations Plus by 82.6% in the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company's stock valued at $26,000 after purchasing an additional 370 shares in the last quarter. nVerses Capital LLC raised its position in shares of Simulations Plus by 1,100.0% during the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company's stock worth $38,000 after purchasing an additional 1,100 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Simulations Plus in the 3rd quarter valued at approximately $59,000. US Bancorp DE grew its holdings in Simulations Plus by 37.0% during the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company's stock valued at $159,000 after buying an additional 1,343 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Simulations Plus during the second quarter worth $206,000. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.